Home Alzheimer’s Disease FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS

The FDA approved the first and only erythroid maturation agent, luspatercept-aamt (Reblozyl), to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS), according to Bristol Meyers Squibb, the agent’s manufacturer.1

In particular, luspatercept is approved to treat anemia failing an erythropoiesis stimulating agent (ESA) and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts (MDS-RS) or with MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T). 

“(This) approval of Reblozyl is an important milestone for a majority of patients with myelodysplastic syndromes who have limited treatment options to address anemia associated with their disease. It also demonstrates our continued commitment to develop innovative products that improve the lives of patients…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments